title: BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
abstract: The bromodomain and extra-terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of critical oncogenes. BET inhibitors have been demonstrated to repress c-Myc expression, and were initially shown to have efficacy in a number of c-Myc-dependent hematologic malignancies. Recent studies have now revealed a broader role for BET inhibitors in hematologic malignancies. In this review, we summarize the efficacy of BET inhibitors in preclinical models of acute leukemia, lymphoma, and multiple myeloma. We also summarize recent results of clinical trials utilizing BET inhibitors in hematologic malignancies, characterize potential resistance mechanisms to BET inhibitors, and discuss potential combination therapies with BET inhibitors in patients with hematologic malignancies.
authors.affiliation: Department of Medicine, Feinberg School of Medicine, Northwestern University.
authors.forename: Sameem M
authors.initials: SM
authors.lastname: Abedin
authors.affiliation: Department of Medicine, Feinberg School of Medicine, Northwestern University.
authors.forename: Craig S
authors.initials: CS
authors.lastname: Boddy
authors.affiliation: Department of Medicine, Feinberg School of Medicine, Northwestern University; Medicine Service, Jesse Brown VA Medical Center; The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
authors.forename: Hidayatullah G
authors.initials: HG
authors.lastname: Munshi
keywords: leukemia; lymphoma; multiple myeloma; resistance mechanisms; toxicity